Pre-made Ensituximab benchmark antibody ( Whole mAb, anti-MUC5AC therapeutic antibody, Anti-MUC5/TBM/leBin Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ensituximab biosimilar, Whole mAb, Anti-MUC5AC Antibody: Anti-MUC5/TBM/leBin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers. The target of the antibody is uncertain and is described as “human colorectal and pancreatic carcinoma-associated antigens”, a set of tumor antigens isolated from human cancers. The target might be Mucin 5AC.
| Products Name (INN Index) | Pre-Made Ensituximab biosimilar, Whole mAb, Anti-MUC5AC Antibody: Anti-MUC5/TBM/leBin therapeutic antibody |
|---|---|
| INN Name | Ensituximab |
| Target | MUC5AC |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Neogenix Oncology,Duke University Medical Center,H. Lee Moffitt Cancer Center and Research Institute,Johns Hopkins Medical Institutions,Montefiore Medical Center,National Cancer Institute (USA),Preci |
| Conditions Approved | NA |
| Conditions Active | Colorectal cancer,Pancreatic cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MUC5AC |
| Package |
